Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals. • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012NTLS119 Principal Investigator Eckfeldt, Craig
Phase NA
Age Group Adult Scope Local
Secondary Protocol No. MT2012-22R
Title MT2012-22R:Collection of Blood Stem and Progenitor Cells from Healthy Adult Donors for Basic Cancer Research
Objective The primary objective of this project is to collect normal donor blood and/or bone marrow samples for the study of potential toxicity of novel treatments for hematologic malignancies.
Treatment No treatment is involved in this study. At the time of routine collection, obtain an additional 10 ml aspirate (bone marrow donor) or an additional 10 ml peripheral blood (mobilized peripheral stem cell donor).
Description Treatments for blood related cancers such as leukemia and myelodysplastic syndrome (MDS) often have toxic effects on normal blood stem and progenitor cells. Normal blood stem and progenitor cells, such as those routinely collected for clinical bone marrow transplantation, provide an essential resource to investigate potential toxic effects in the research laboratory. Bone marrow or blood that is donated for this study will be used by researchers at the University of Minnesota to evaluate the effects of novel treatments for blood related cancers on normal blood stem and progenitor cells. Researchers may analyze the growth, gene expression, proteins, or DNA of the bone marrow or blood cells that are collected to analyze how the cells respond to novel cancer treatments.
Key Eligibility Any consenting adult (> 18 years of age) donor undergoing bone marrow harvest or mobilized peripheral blood stem cell collection.
Applicable Disease Sites Acute myeloid leukemia (AML)
Hematologic Malignancies
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility A signed consent and HIPAA authorization are required.
Treatment Type Basic Science
Contact Craig Eckfeldt Phone:612-624-0123
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on